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Abstract  
Background 
Combination antiretroviral therapy (ART) suppresses viral replication in HIV-infected children. 
The growth of virologically suppressed children on ART has not been well documented. We 
aimed to develop dynamic reference curves for weight-for-age z scores (WAZ) and height-for-
age z scores (HAZ). 
Methods  
Children aged <11 years at ART initiation with continuously undetectable viral loads (<400 
copies/ml) treated at seven South African ART programs with routine viral load monitoring were 
included. We used multilevel models to define trajectories of WAZ and HAZ up to 3 years and 
developed a web application to monitor trajectories in individual children.  
Results 
A total of 4,876 children were followed for 7,407 person-years. Analyses were stratified by 
baseline z-scores and age, which were the most important predictors of growth response. The 
youngest children showed the most pronounced increase in weight and height initially but catch-
up growth stagnated after 1-2 years. Three years after starting ART, WAZ ranged from -2.2 
(95% Prediction interval -5.6 to 0.8) in children with baseline age >5 years and z-score <-3 to 0.0 
(-2.7 to 2.4) in children with baseline age <2 years and WAZ >-1. For HAZ the corresponding 
range was -2.3 (-4.9 to 0.3) in children with baseline age>5 years and z-score <-3 to 0.3 (-3.1 to 
3.4) in children with baseline age 2-5 years and HAZ >-1. 
Conclusions 
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We have developed an online tool to calculate reference trajectories in fully suppressed children. 
The web application could help to define ‘optimal’ growth response and identify children with 
treatment failure. 
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Measuring a child’s weight and height over time and comparing it to a reference is a simple way 
of assessing his or her growth and health. In HIV-infected children in settings with few 
resources, growth monitoring is used to identify children eligible for antiretroviral therapy 
(ART) and weight and height trajectories are often the only information on whether a child is 
responding to ART 1,2,3. 
Data on the association between growth and virologic response to ART are however 
conflicting 4. Some studies showed that virologic control leads to improved growth, while no 
associations were found in others 3,5. Studies from Malawi 6 and Uganda 7 reported that 
undernourished and stunted children often do not reach normal weight-for-age (WAZ) and 
height-for-age (HAZ) scores under ART. However, virologic response was not assessed in these 
studies and the growth trajectories in African HIV-infected children with suppressed viral 
replication are not well defined. In contrast, children from Europe and the US, where regular 
viral load monitoring is used, reached normal values within two years of initiating therapy 8.  
African settings differ with regard to many factors related to growth: children generally 
start ART at an age of 5 to 6 years 9, often with more advanced disease. Detrimental 
environmental factors such as co-infections, under-nutrition and food insecurity are common 
10,11
. Using data from the large pediatric IeDEA Southern Africa (IeDEA-SA) collaboration we 
aimed to describe growth in children with consistently suppressed HIV viremia, to derive 
reference standards of z-score trajectories and to make these available in a web application that 
displays expected growth up to three years on ART for individual children. 
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MATERIALS AND METHODS 
International epidemiological Databases to Evaluate AIDS  
IeDEA-SA is a collaboration of 24 ART programs in six countries in Southern Africa 
(www.iedea-sa.org) 12. Data are collected at ART initiation (baseline) and follow-up visits using 
standardized instruments. All sites have ethical approval to collect data and participate in 
IeDEA-SA. In the present study we used the data merged up to the first of January 2014 and 
included seven IeDEA-SA sites with at least 100 children that had started ART in South Africa, 
the only country within the IeDEA-SA collaboration where viral load was routinely monitored. 
Anthropometric measurements were generally scheduled to be done every 4-12 weeks. Viral 
loads were measured according to the South African guidelines as follows: semi-annually prior 
to 2010 and then from 2010-2012 at 6 and 12 months after ART initiation and then yearly.  
These primary sites include the Khayelitsha ART Program, McCord Hospital, Red Cross 
Children's Hospital, Hlabisa HIV Care and Treatment Program, Harriet Shezi Clinic, Rahima 
Moosa Mother and Child Hospital and Tygerberg Academic Hospital. An eighth site 
(Kheth’Impilo) which joined IeDEA only recently was used for model validation only.  
 
Eligibility Criteria and Definitions 
We included ART-naïve children aged <11 years who initiated treatment with at least three 
antiretroviral drugs and had undetectable viral load measurements only during the first three 
years on ART (all viral load values <400 copies/ml). Children did not need to have three years of 
follow-up to be included in the analysis. We included children who died or transferred-out 
during follow-up on ART. We excluded children without any anthropometric measurement after 
start of ART and children who were transferred from another site. A child was considered lost to 
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follow-up if the time between the last visit and the closing date of the cohort was longer than 6 
months. Weight and height measurements were converted to age- and sex-adjusted z-scores 
using the WHO reference population 2007 13. Underweight was defined as weight-for-age 
(WAZ) <–2 and stunting as height-for-age (HAZ) <–2. We took weight and height 
measurements and CD4 cell counts closest to the starting date of ART (-6 months/+1week) as 
baseline values. Immunodeficiency was defined as in the WHO case definitions of HIV 14.    
 
Statistical analysis and modeling 
The analysis was conducted using data from all 7 primary sites. The WAZ and HAZ z-score 
trajectories were analyzed using second order fractional polynomials 15. The same approach was 
used in an earlier study in Malawi 2. We used a model including all patients to determine which 
variables were most predictive of anthropometric trajectories and then stratified the analysis by 
these variables. In each stratum the best fitting second order fractional polynomial was selected 
based on the deviance criterion 15. Separate analyses were performed for the different strata. No 
interaction terms were included. We then extended the model to a Bayesian multi-level model 16 
taking into account between cohort and between patient variability. The model fit was visually 
assessed by plotting the 95% prediction intervals and the observed trajectories for individual 
children. We assessed the model for over-fitting by randomly splitting the data into a training 
data set (90% of patients) and a test data set (10% of patients). We performed the analysis on the 
training set and assessed how many measurements of the test dataset were within the 95% 
prediction interval.  
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We validated the model using data from the independent cohort (Kheth’Impilo) and checked 
how many measurements of the validation data were within the 95% prediction interval. We 
report all validation results after 1 and 3 years of follow-up.  
Based on the predictive distribution of growth trajectories obtained from the training data set, a 
web application was developed. The joint predictive distribution of location and scale parameters 
was approximated by a normal inverse Gamma distribution and served as the prior distribution 
for the growth trajectories of a new child. Available anthropometric measurements were used to 
update the prior as new measurements become available. The growth trajectories for a given 
child were then predicted using this prior distribution and past z-scores (for more details see 
http://iedea-sa.org). All analyses were performed in R version 3.0.2 17, Stata version 11 18 and 
WinBUGS version 1.4.3 19.  
 
RESULTS 
Study population and baseline characteristics 
Of 12,476 children followed up in the 7 primary sites, 7,130 (57.1%) children had continuously 
undetectable viral load, and 5,423 had a weight and/or height measurement at the start of ART. 
Among these, 4,876 were randomly selected for the training dataset and 547 for the test dataset 
(Figure, Supplemental Digital Content 1, http://links.lww.com/INF/C206). The number of 
children included in analyses ranged from 74 children from Hlabisa in KwaZulu-Natal to 1,944 
children from the Harriet Shezi clinic in Soweto. The median age of the children was 3.7 years 
and about half (2440 children; 50.0%) were female (Table 1). At baseline most children (4,871 
children; 99.9%) had a weight measurement, and 3,340 children (68.5%) had a height 
measurement. A substantial proportion of children with measurements were underweight (1,805 
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children; 37.1%), stunted (1,842; 55.1%) and had evidence of severe immunodeficiency at 
baseline (1,831; 51.0%) (Table 1).  
In the first three years after starting ART, 217 (4.5%) children died, 241 (4.9%) were lost to 
follow up and 808 (16.6%) were transferred to another clinic. The median follow-up between 
ART initiation and the last available anthropometric measurement was 11 (interquartile range 1-
29; range 0-36) months. During 5,136 years of follow-up, 42,258 weight and 29,145 height 
measurements were recorded. A total of 3,340 children had a baseline height available and were 
thus included in the analysis for HAZ. The children with baseline WAZ did not substantially 
differ from the children with baseline HAZ. 
The validation dataset consisted of 480 children with available baseline weight or height from 
the Kheth’Impilo cohort. All children had baseline WAZ recorded and 35 (7.3%) had baseline 
HAZ recorded. Children in the validation data were older, had lower baseline WAZ and HAZ, 
were in less severe WHO stages, were included more recently, were more likely on NNRTI-
based regimens and were less often lost to follow-up or transferred out than the children in the 
primary dataset.  
 
Growth trajectories for WAZ and HAZ 
Baseline z-scores and age were the strongest predictors of growth response overall. Baseline 
viral load, CD4 and WHO stage were also associated with growth, but with a small effect 
estimate. For the population projections, we therefore calculated separate growth curves for 
children with z-scores < -3, -3 to <-2, -2 to <-1, or >-1 and age groups <2 years, 2 to <5 years 
and 5 to <11 years. The youngest children showed the most pronounced increase in weight and 
height initially but in all children catch-up growth stagnated after the first one or two years. 
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Figure 1 shows mean WAZ with 95% prediction intervals (PrI) by baseline z-scores and age 
group up to 3 years after ART start. Three years after starting ART, WAZ ranged from -2.2 (95% 
PrI -5.6 to 0.8) in children aged 5 years or older who started with a baseline z-score of less than -
3 to 0.0 (95% PrI -2.7 to 2.4) in children aged less than 2 years with a baseline WAZ greater than 
-1. For HAZ the corresponding range was -2.3 (95% PrI -4.9 to 0.3) in children aged 5 years or 
older who started with a baseline z-score of less than -3 to 0.3 (95% PrI -3.1 to 3.4) in children 
aged 2 to 5 years with a baseline HAZ larger than -1 (Figure 2).   
Overall, the model fitted well in the test sample with 95% (93% during the first year) of 
observations included in the 95% prediction interval for WAZ. This percentage differed between 
subgroups. It was 89% (87% during the first year) for 0-2 year olds with baseline WAZ between 
-2 and -1 and 98% (97% during the first year) for 2-5 year olds with baseline WAZ less than -
3.The model also fitted well for HAZ with 92% (91% during the first year) of observations in the 
prediction interval. This percentage was 76% (72% during the first year) for 0-2 year olds with 
baseline HAZ larger than -1 and 99% (97% during the first year) for 2-5 year olds with baseline 
HAZ between -2 and -3. In the independent validation sample, the model fitted well, with 92% 
(90% during the first year) of observations in the 95% prediction interval for WAZ. This 
percentage was 89% (87% during the first year) for 6-10 year olds with baseline WAZ larger 
than -1 and 96% (95% during the first year) for 2-5 year olds with baseline WAZ between -2 and 
-1. The validation sample only had data on HAZ for 35 patients with a total of 81% (81% during 
the first year) of observations in the 95% prediction interval.  
 
Predictions for individual children- web interface  
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Figure 3 shows the output of the web application, which is available online 
(http://growthapp.iedea-sa.org). We also provide a step-by-step manual which is available online. 
The web application can be used to predict WAZ and HAZ trajectories by baseline age and z-
score up to 3 years after starting ART. The example shows a hypothetical child aged between 2 
and 5 years whose baseline WAZ was below -3 at ART initiation. The user entered either 1, 3 
(the minimally required number for individual trajectories), 9 or 16 weight measurements 
(shown as black triangles in panels A, B, C, and D of Figure 3). The likely evolution of WAZ is 
then shown for up to 3 years after ART initiation. The predictions for a particular child are 
adjusted each time more values are entered. The expected range of values for an HIV positive 
child with the same baseline age and WAZ categories and suppressed viral load values are 
shown as shaded areas. 
 
DISCUSSION 
Main findings 
We provide growth reference curves up to 3 years after starting ART both at the individual and 
at the population level. The reference was developed in children who never had detectable viral 
load and growth therefore should have been closer to optimal than in children with detectable 
viral load. While the population-level estimations may serve as a reference for children of a 
certain age and z-score at start of antiretroviral therapy, the individual-level predictions take the 
history of previous measurements into account when making predictions. The individual-level 
predictions may therefore be more useful for children who deviate from the average and may be 
used as early warning indicators for treatment failure and comorbidities. The population-level 
predictions show that despite virologic suppression and initial catch-up growth, the median WAZ 
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does not reach normal values. After about 1.5 years on ART, catch-up growth stops and in 
particular older children with low baseline z-scores catch-up very slowly. For HAZ the increase 
is less pronounced but continuous over a longer period in the older age groups. 
 
 
Comparisons to other studies 
The overall pattern in weight and height gain is similar to a previous study within the IeDEA 
collaboration where data from sites with and without viral load monitoring were combined 20. In 
both analyses WAZ increased rapidly in the first year of ART but stagnated thereafter, whereas 
HAZ increased continuously over time. However, in contrast to the previous analysis where no 
difference between viral load and non-viral load sites was found, we now found that WAZ in 
virologically suppressed children seem to be higher than in suppressed and non-suppressed 
combined. For example in children with a baseline WAZ of < -3, estimated WAZ at three years 
ranged from -1.5 to -2.2 across age groups in our analysis compared to -2.1 across all ages in the 
previous analysis. For HAZ no difference was found (ranging from -2 to -2.3 across age groups 
in our analysis compared to -2.3 previously). However, estimates between studies were not 
directly comparable since analyses were not stratified by age previously and loss to follow-up 
was lower (4.9% in our analysis versus 14.5% previously).  
It remains unclear why catch-up growth in weight stops after about 1.5 years on therapy despite 
the continuous virologic suppression. In addition to unrecorded factors (e.g. socioeconomic 
status, nutrition), chronic immune-activation due to HIV or ART side effects may also play a 
role. A study in adults has shown that mitochondrial toxicity due to D4T may lead to weight loss 
in adults 21 but to our knowledge no data have been reported on children. In our study the same 
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downwards trend in growth was apparent when children on D4T regimens were excluded from 
the analysis (data not shown). An analysis from rural Zambia found a similar growth pattern for 
both weight and height to ours. In the Zambian study mean WAZ increased rapidly from -2.4 at 
ART initiation to -1.3 after 6 months and decreased slightly to -1.7 after two years. During the 
same time mean HAZ increased almost linearly from -3.5 to -2.1. In contrast to us, other studies 
found a linear increase in WAZ during the first two years of ART in children older than 5 years 
22
 and in urban settings 23.  
 
Comparison to HIV negative children 
Unfortunately we were unable to compare our results to those from HIV negative children from 
the same setting. One study from Kinshasa found lower WAZ in HIV positive than HIV negative 
children: at 18 months WAZ was -2.3 in HIV positive compared to  
-1.3 in HIV negative children – irrespective if the mother was HIV positive or not. For HAZ the 
difference persisted but was only about half a z-score lower in HIV positive vs negative children 
24
. Similarly in an Ugandan trial HIV infected children weighed less and were shorter during the 
whole 5 years of follow-up after birth 25. In these studies children were followed from birth and 
no distinction was made between those with and without virologic suppression.  
 
Predictors of growth response 
Many factors may influence growth and simply having a continually suppressed viral load does 
not imply that normal growth will be achieved. Growth response has been shown to be better in 
younger children 26,27, and in children with low CD4 cell percentages and advanced stage of 
disease 28,29. Other individual- and site-level factors associated with poor growth, but not 
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recorded in our database, include co-infections (such as Tuberculosis) and other comorbidities, 
low socioeconomic status and poor nutrition or food insecurity or the lack of food 
supplementation programs 30,31.  
 
Strengths and limitations 
The strengths of the analysis are that children from many sites and settings were included and 
that the characteristics of the children at start of ART are typical for the region. We used state of 
the art statistical analysis techniques and validated the prediction in an independent sample. 
Although viral load and non-viral load sites may differ with regard to many factors, our results 
may serve as a reference in sites where viral load monitoring is not available.  
The study also has a number of limitations. Since the analysis was restricted to sites where viral 
load monitoring is available in order to assess virologic suppression, all included sites were in 
South Africa where the standard of care is higher than in other sites and the results may not 
necessarily be generalizable to other settings. Our selection criteria also restricted the available 
sample size and the follow-up duration; in particular the number of children with height 
measurements was limited. Due to this limited sample size and since weight and height 
measurements were not always available at the same time point, an analysis of WHZ was not 
possible. Also children must have had at least 3 anthropometric measurements to make 
individual-level predictions of growth response. There was considerable loss to follow-up, which 
limited the precision of the population estimates during the third year. Although we included 
only virologically suppressed children, which indicates good adherence, adherence was not 
explicitly recorded and intermittent poor adherence including unmeasured viral failures are 
possible. Our results represent trajectories of children who remained in care. Children who were 
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lost to follow-up, who transferred-out or who died may have different growth responses. If sicker 
patients are more likely to get lost, our analysis overestimates growth response. We were unable 
to compare PI based regimen and NNRTI based regimen, because the distribution of regimens 
were unbalanced across age groups. Finally, the model cannot predict the probability of viral 
failure. 
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Figure Legend 
Figure 1: Weight for age z-scores trajectories by z-score and age at start of antiretroviral 
therapy in children with consistently undetectable viral load. These curves represent 
population-level predictions and should not be used for individual treatment monitoring. The 
black lines are predicted response curves, the dark blue areas are 50% prediction intervals and 
the light blue areas are 95% prediction intervals. A total 4871 children from seven clinics in 
South Africa were included.  
 
Figure 2: Height for age z-scores trajectories by z-score and age at start of antiretroviral therapy 
in children in children with consistently undetectable viral load. These curves represent 
population-level predictions and should not be used for individual treatment monitoring. The 
black lines are predicted response curves, the dark blue areas are 50% prediction intervals and 
the light blue areas are 95% prediction intervals. 3340 children from 7 sites in South Africa were 
included.  
 
Figure 3: Illustration of the web-interface - example of individual predictions of weight for age 
growth trajectory.  
Predictions up to 3 years after start of antiretroviral therapy can be made according to the 
characteristics of the child at start of antiretroviral therapy and weight measurements thereafter. 
Predictions are based on predictive distributions from the Bayesian multilevel model.  
The example shows the actual measured values for one particular child with a baseline age of 2 
to 5 years and a baseline weight for age z score  
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< -3. Observed values (dots) and prediction intervals (median, 50% and 95%) for that child are 
shown. The shaded area shows the prediction intervals for any child with the same baseline age 
and z-scores. The predictions for a particular child are adjusted each time more values are 
entered. 
In panel A, only the first weight measurement was available and population-level prediction 
intervals are shown. In panel B, three weight measurements were available and an individual-
level prediction (black) is shown on top of the population-level predictions. In panel C, 9 
measurements were available and in panel D all measurements are shown. The prediction 
intervals for that particular child are based on the known values shown as dots. 
These predictions are implemented both for weight for age and height for age and can be 
accessed from the following webpage: http://growthapp.iedea-sa.org. The user can introduce his 
own values of interest and must then specify if the predictions are for a child from a cohort 
which was used to develop the model or if the child comes from an external cohort. 
 
SDC figure: Flowchart of included and excluded children 
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Table 1: Characteristics of children starting antiretroviral therapy. 
Characteristic 
All 
children 
Weight-for-
age analysis 
Height-for-
age analysis 
Validatio
n data 
N=4,876 N=4,871 N=3,340 N=480 
Site 
Harriet Shezi, 
Soweto 1,944 1,942 1,907 - 
Khayelitsha, Cape 
Town 980 979 128 - 
Red Cross, Cape 
Town   631 631 86 - 
Tygerberg, Cape 
Town 162 161 111 - 
McCord, Durban 689 689 683 - 
Hlabisa, Kwa Zulu 
Natal 74 74 56 - 
Rahima Moosa, 
Johannesburg 396 395 369 - 
Khethimpilo,  Cape 
Town   - - - 480 
Age, median 
(IQR), years 
3.7 (1.6-
6.3) 3.7 (1.6-6.3) 4.1 (1.6-6.6) 
5.6 (3.4-
7.6) 
 Age group, n 
(%) 
<2 years 
1,679 
(34.4)  1,676 (34.4)  1,143 (34.2) 81 (16.9) 
2 to 5 years 
1,253 
(25.7)  1,251 (25.7)  818 (24.5) 113 (23.5) 
6 to 10 years 
1,944 
(39.9)  1,944 (39.9)  1,379 (41.3) 286 (59.6) 
Sex, n (%) Female 2,440 (50)  2,440 (50.1)  1,669 (50) 248 (51.7) 
Weight-for-age 
z-score, n (%) 
 < -3 946 (19.4) 946 (19.4) 748 (22.4) 261 (54.4) 
 -3 to < -2 859 (17.6) 859 (17.6) 653 (19.6) 121 (25.2) 
 -2 to < -1 
1286 
(26.4) 1286 (26.4) 883 (26.5) 59 (12.3) 
 >=-1 
1780 
(36.5) 1780 (36.5) 1051 (31.5) 39 (8.1) 
Height-for-age z-
score 
 < -3 917 (27.5) 914 (27.4) 917 (27.5) 21 (60) 
 -3 to < -2 925 (27.7) 925 (27.7) 925 (27.7) 10 (28.6) 
 -2 to < -1 815 (24.4) 814 (24.4) 815 (24.4) 2 (5.7) 
 >=-1 683 (20.4) 682 (20.4) 683 (20.4) 2 (5.7) 
CD4 percentage Missing data 1320 1320 698 319 
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median (IQR) 
14.5 (9-
21.1) 14.5 (9-21.1) 14.2 (8.8-21) 15 (10-21) 
Immunodeficien
cy **, n (%) Missing data 1288 1288 691 273 
Not significant 653 (18.2) 652 (18.2) 478 (18) 34 (16.4) 
Mild 454 (12.7) 454 (12.7) 336 (12.7) 25 (12.1) 
Advanced 650 (18.1) 649 (18.1)  479 (18.1) 49 (23.7) 
Severe 1831 (51) 1828 (51) 1356 (51.2) 99 (47.8) 
WHO clinical 
stages, n (%) Missing data 785 782 598 113 
Stage 1 287 (7) 287 (7) 126 (4.6) 33 (9)  
Stage 2 462 (11.3) 462 (11.3) 267 (9.7) 155 (42.2)  
Stage 3 
2237 
(54.7) 2235 (54.7) 1475 (53.8) 175 (47.7)  
Stage 4 1105 (27) 1105 (27) 874 (31.9) 4 (1.1) 
Year of ART 
start, n (%) 1999-2004 315 (6.5) 315 (6.5) 274 (8.2) 0 (0) 
2005-2009 3269 (67) 3265 (67) 2328 (69.7) 240 (50) 
2010-2013 
1292 
(26.5) 1291 (26.5) 738 (22.1) 240 (50) 
Type of regimen, 
n (%) 
NNRTI-based 
2762 
(56.7) 2760 (56.8) 1945 (58.3) 341 (71) 
PI-based 
2027 
(41.6) 2024 (41.6) 1324 (39.7) 68 (14.2) 
Other/unknown 78 (1.6) 78 (1.6) 70 (2.1) 71 (14.8) 
Outcome, n (%) 
*** Death 217 (4.5) 216 (4.4) 163 (4.9) 8 (1.7) 
Loss to follow-up 241 (4.9) 241 (4.9) 85 (2.5) 0 (0) 
Transfer-out 808 (16.6) 808 (16.6) 661 (19.8) 0 (0) 
 
* no baseline weight or height available; ** WHO case definitions 14 *** censored after 3 years;
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Figure 1. 
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Figure 2. 
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Baseline weight available:
Included in population-level 
WAZ analysis (N = 4,871)
Baseline height available:
Included in population-level 
HAZ analysis (N = 3,340)
All children
(N = 12,476)
Suppressed children
(N = 7,130)
Included children
(N = 5,423)
Viral load ≥ 400 copies/ml
(Multiple times: N = 2,900 ;
Just once: N = 2,446)
No baseline weight or height
(N = 1,707)
Training data
(N = 4,876)
Test data
(N = 547)
≥3 weight measurements: 
Included in individual-level 
WAZ analysis (N = 3,429)
≥3 height measurements: 
Included in individual-level 
HAZ analysis (N = 2,548)
Figure S1: Flowchart of included and excluded children
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